Professional Documents
Culture Documents
Decontamination/Cleaning Validation
Copyright ISPE 2008
This case study
will review the
main items of a
decontamination
protocol for the
renovation of a
beta-lactam
production
facility into a
non-beta-lactam
production
facility.
Case Study: Beta-Lactam
Decontamination and Cleaning
Validation of a Pharmaceutical
Manufacturing Facility
by Hisao Takahashi, PE, Hiroshi Sakai, and
Dr. Daniel H. Gold
Introduction
A
question frequently asked by former
producers of beta-lactam antibiotics
is: Can a facility that produced beta-
lactams be successfully decontami-
nated and renovated for the production of non-
beta-lactams, meeting all regulatory expecta-
tions after conversion for absence of detectable
beta-lactam residues?
Toyama Chemical Co., Ltd. planned to con-
vert a synthesis factory (factory no. 6) into a
clinical supplies drug substance and an initial
active pharmaceutical ingredient manufactur-
ing facility that would meet cGMP regulations.
However, there was a potential for cross-con-
tamination with beta-lactams, because the syn-
thesis factory had been in use for a number of
years producing Cephalosporin entities. There
were five beta-lactam entities previously pro-
duced in this factory, code named P15, P16,
P23, P24 and DX-B.
To beneficially use this factory, Toyama de-
veloped a comprehensive decontamination pro-
tocol. After preparing the protocol, Toyama
contacted the US FDA for discussion of the
proposal and agreement of the procedures to be
Figure 1. Factory profile
and personnel, material,
and product flows.
Reprinted from
PHARMACEUTICAL ENGINEERING